Clinical Trial Update: A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of HC-1119 Soft Capsules in metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• HC-1119 Soft Capsules (HC-1119)

Snippet

Sponsor: Hinova Pharmaceuticals Inc. | Conditions: MCRPC | Phase 3 | Status: RECRUITING